

Relationships With Industry

Name: **Shaun Goodman**

Last updated: **March 23, 2026**

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company generates revenue for the University of Alberta	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Canadian VIGOUR Centre (including support from CSL, Boehringer-Ingelheim, and Regeneron)	2010-present	AEGIS-2 (2016-2025), EMPACT- MI (2020-2024), OCEANIC-AF (2021-2025), POSIBIL-6 (2022-present), ROXI-ATLAS, -INCLINE, and -EVEREST trials	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Including quarterly stipend directed to the St. Michael's Physician's Association
Duke Clinical Research Institute (including support from Daiichi-Sankyo/American Regent, CSL, Boehringer-Ingelheim, Regeneron, and Amaryn)	2010-present	EMPACT-MI (2021-2024), HEART-FID (2019-2023), KARDIA-3 (2024-25), ZENITH (2025-present), ROXI-ATLAS (2025-present) and ROXI-INCLINE (2026-present) trials	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Including National Coordinator and DMC activities
Canadian Heart Research Centre and MD Primer	1996-present	Multiple clinical trials, observational registries, and continuing professional development programs	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Including quarterly stipend directed to the St. Michael's Physician's Association (1996-2022)
New York University	2012-present	ISCHEMIA/ISCHEMI	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Novo-Nordisk	2019-present	SOUL and FLOW trials	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Data Monitoring Committee member
Daiichi-Sankyo/American Regent	2017-2023	HEART-FID trial	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Data Monitoring Committee member
University Court of the University of Edinburgh	2014-present	ACS Risk Working Group Canadian study	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
CSL Behring (through PERFUSE Research Institute)	2016-2025	AEGIS-II	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Executive Steering Committee member
Esperion (through Cleveland Clinic Coordinating Center for Clinical Research [C5])	2018-2023	CLEAR OUTCOMES	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
Boehringer-Ingelheim	2020-present	EMPACT-MI	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
Bayer	2020-2023	TRANSECT AF	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Principal Investigator
Novartis	2020-2023	HF-IDOC	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Study Chair
Bayer	2021-2025	OCEANIC-AF	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Executive Steering Committee member
CSL Behring (through the Duke Clinical Research Institute [DCRI])	2022-present	POSIBIL-6	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Canadian site operations
TIMI Study Group (Brigham Health; previously through Anthos Therapeutics, currently through Novartis)	2020-present	AZALEA-TIMI 71 (2020-present) and LILAC (2022-present) trials	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
CYTE	2022-present	GARDENIA Registry (2022-2024) and SEAFRONT Registry (2025-present)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
Idorsia	2021-present	SOS-AMI (2021-present)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member

Relationships With Industry

Name: **Shaun Goodman**

Last updated: **March 23, 2026**

Company/(Companies):	Period of Support	Name of Project	1) A research grant or contract from this Company generates revenue for the University of Alberta	2) A research grant or contract from this Company partially supports my research projects	3) Educational activities or lectures for this Company generates revenue for the University of Alberta		4) Consulting or other services for this company generates personal income		5) I receive significant personal royalties from this Company	6) I have equity in this Company	Comments
					<\$10K	>\$10K	<\$10K	>\$10K			
Alnylam, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Eli Lilly, HLS Therapeutics, Merck, Novartis, Novo Nordisk A/C, Pendopharm/Pharmascience, Pfizer, Prolocor Inc., Regeneron, Roche, Sanofi, Tolmar Pharmaceuticals, Viartis	2016-present	Consulting/Advisory Boards/Rounds/Slide set development	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
Eli Lilly	2025-present	ACCLAIM and MOVE Lp(a)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Data Safety Monitoring Committee member
Regeneron	2025-present	ROXI-ATLAS (2025-present)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Steering Committee member
Merck	2026-present	EHR-LOCALE	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Study Chair for an Investigator-initiated clinical trial
Jewish General Hospital/ CIUSSS Centre-Ouest-de-l'Île-de-Montreal	2024-present	ASAP (2024-present)	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	Data Safety Monitoring Committee member

Monetary amounts are on an annual basis.